Cabergoline

Research records

Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.

Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.

Cabergoline

An FDA-approved dopamine agonist used to treat hyperprolactinemic disorders.

Evidence category: Regulator / guideline. This describes the source category, not approval or certainty.

Regulatory statement in source: FDA-approved.

Cabergoline is a long-acting dopamine agonist approved by the FDA under the brand name Dostinex for treatment of hyperprolactinemic disorders, whether idiopathic or due to pituitary adenomas. It exerts direct inhibitory effects on prolactin secretion through D2 receptor agonism. FDA labeling warns against postpartum lactation suppression due to serious adverse reaction risks.

Benefits reported in the imported source

• Treatment of hyperprolactinemic disorders, idiopathic or pituitary adenoma-related.

Risks and limits

• Black box warning against use for postpartum lactation suppression
• Contraindicated with D-antagonists (phenothiazines, butyrophenones, metoclopramide)
• Cardiac valvulopathy risk with long-term use

Source bottom line: FDA-approved dopamine agonist for hyperprolactinemia with black box warning limiting certain uses.

Uncertainty: Reference information only. Not medical advice.

Study protocols — reports, not instructions

No study protocol recorded in this snapshot. This does not establish that no study exists.

Community and practice descriptions

Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.

No community description recorded. This entry has no final B-82 outcome record; it is not a researched-empty finding.

Pharmacokinetic context

Historical half-life estimate: 66 hours. FDA label, Dostinex: elimination half-life estimated from urinary data, 63 to 69 hours (midpoint shown — the range rounds to the same day count) Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.

Source references

• DOSTINEX (cabergoline) Label - FDA
• Cabergoline - Drugs.com Monograph (availability check 2026-10-15: source not retrieved; HTTP 403)